The epidemiology of tuberculosis and resistance to anti-tuberculosis drugs

被引:0
|
作者
Khaled, NA [1 ]
Enarson, D [1 ]
Billo, N [1 ]
机构
[1] Union Int TB & Malad Resp, F-75006 Paris, France
关键词
tuberculosis; epidemiology; resistance;
D O I
暂无
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Tuberculosis is once more a subject of world wide preoccupation; since 1985 a disturbing recrudescence of this disease has been noted in numerous countries related to population growth and the worsening of poverty in those countries without natural resources, and disadvantaged groups living on the margins of society in rich countries, along with the occurrence of an epidemic of HIV (VIH). In numerous developed countries where tuberculosis no longer represents a public health problem, the care services have little by little been closed or re-oriented and the principles of treatment of tuberculosis have been forgotten. The direct consequence of this has often been inadequate treatment and its corollary; the emergence of strains multiresistant to Isoniazid and Rifampicin. If the current epidemiological tendencies are confirmed and no supplementary action is taken, the WHO (OMS) has estimated that during the ten years between 1990 and the millennium there will be 88 million new cases of tuberculosis and 30 million people will die of tuberculosis. However the tendencies can be reversed and tuberculosis could still be eliminated. The struggle against tuberculosis is a world wide emergency and the hope of controlling the situation before an increase in multiresistant strains which would render the trend irreversible, rests on a general application of correct and coherent national programmes. Such a programme as the UICTMR model had already been carried out as has the proof of their efficacy.
引用
收藏
页码:S8 / S18
页数:11
相关论文
共 50 条
  • [21] Availability of anti-tuberculosis drugs in Europe
    Sotgiu, Giovanni
    D'Ambrosio, Lia
    Centis, Rosella
    Bothamley, Graham
    Cirillo, Daniela M.
    De Lorenzo, Saverio
    Guenther, Gunar
    Kliiman, Kai
    Muetterlein, Ralf
    Spinu, Victor
    Villar, Miguel
    Zellweger, Jean-Pierre
    Sandgren, Andreas
    Huitric, Emma
    Lange, Christoph
    Manissero, Davide
    Migliori, Giovanni Battista
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (02) : 500 - 503
  • [22] Prospects for new anti-tuberculosis drugs
    Duncan, K
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1997, 49 : 21 - 23
  • [23] Adverse Reaction to Anti-tuberculosis Drugs
    Chantaphakul, H.
    Cheungpasitporn, W.
    Ruxrungtham, K.
    Klaewsongkram, J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (02) : AB154 - AB154
  • [24] Clinical development of anti-tuberculosis drugs
    Mitchison, D. A.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (03) : 494 - 495
  • [25] Manifestations of hypersensitivity to anti-tuberculosis drugs
    Benbetka, Yacine
    Souilah, Souad
    Fissah, Aziza
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [26] Pharmacokinetics of Anti-tuberculosis Drugs in Children
    Geetha Ramachandran
    A. K. Hemanth Kumar
    Soumya Swaminathan
    The Indian Journal of Pediatrics, 2011, 78 : 435 - 442
  • [27] DIAZEPAM INTERACTION WITH ANTI-TUBERCULOSIS DRUGS
    OCHS, HR
    GREENBLATT, DJ
    ROBERTS, GM
    DENGLER, HJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (05) : 671 - 678
  • [28] Pharmacokinetics of Anti-tuberculosis Drugs in Children
    Ramachandran, Geetha
    Kumar, A. K. Hemanth
    Swaminathan, Soumya
    INDIAN JOURNAL OF PEDIATRICS, 2011, 78 (04): : 435 - 442
  • [29] INTERACTION OF DIAZEPAM WITH ANTI-TUBERCULOSIS DRUGS
    OCHS, HR
    GREENBLATT, DJ
    ROBERTS, GM
    DENGLER, HJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (02) : 270 - 270
  • [30] Human Tuberculosis II. M. tuberculosis Mechanisms of Genetic and Phenotypic Resistance to Anti-Tuberculosis Drugs
    Sgaragli, Giampietro
    Frosini, Maria
    CURRENT MEDICINAL CHEMISTRY, 2016, 23 (12) : 1186 - 1216